Literature DB >> 8100709

Interaction of secretory leukocyte protease inhibitor with proteinase-3.

N V Rao1, B C Marshall, B H Gray, J R Hoidal.   

Abstract

Secretory leukocyte protease inhibitor (SLPI) is a 12 kD nonglycosylated serine antiproteinase secreted by cells of mucosal surfaces. In human lung, SLPI is present in the respiratory epithelium. It is the major barrier to tissue destruction mediated by the polymorphonuclear leukocyte (PMN) serine proteinases, elastase and cathepsin G, within the upper respiratory tract. We have recently described a third PMN serine proteinase, proteinase-3, that like elastase causes lung matrix destruction and experimental emphysema. The current studies examine interactions between SLPI and proteinase-3. The results show that: (1) SLPI and its reactive-site variants have no or minimal inhibitory activity against proteinase-3; (2) native SLPI does not complex with proteinase-3; (3) proteinase-3 selectively degrades both native and oxidized SLPI; (4) the cleavage of SLPI by proteinase-3 occurs at the peptide bond COOH-terminal to Ala-16 in the NH2-terminal domain of SLPI.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100709     DOI: 10.1165/ajrcmb/8.6.612

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  13 in total

1.  Converting enzyme-independent release of tumor necrosis factor alpha and IL-1beta from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3.

Authors:  C Coeshott; C Ohnemus; A Pilyavskaya; S Ross; M Wieczorek; H Kroona; A H Leimer; J Cheronis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

2.  Human neutrophil elastase induces hypersecretion of mucin from well-differentiated human bronchial epithelial cells in vitro via a protein kinase C{delta}-mediated mechanism.

Authors:  Jin-Ah Park; Fang He; Linda D Martin; Yuehua Li; Brian N Chorley; Kenneth B Adler
Journal:  Am J Pathol       Date:  2005-09       Impact factor: 4.307

Review 3.  Neutrophil proteinase 3 and dipeptidyl peptidase I (cathepsin C) as pharmacological targets in granulomatosis with polyangiitis (Wegener granulomatosis).

Authors:  Brice Korkmaz; Adam Lesner; Stephanie Letast; Yassir K Mahdi; Marie-Lise Jourdan; Sandrine Dallet-Choisy; Sylvain Marchand-Adam; Christine Kellenberger; Marie-Claude Viaud-Massuard; Dieter E Jenne; Francis Gauthier
Journal:  Semin Immunopathol       Date:  2013-02-06       Impact factor: 9.623

4.  Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation.

Authors:  Sinéad Weldon; Paul McNally; Noel G McElvaney; J Stuart Elborn; Danny F McAuley; Julien Wartelle; Abderrazzaq Belaaouaj; Rodney L Levine; Clifford C Taggart
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

5.  Antiproteases as therapeutics to target inflammation in cystic fibrosis.

Authors:  Derek J Quinn; Sinéad Weldon; Clifford C Taggart
Journal:  Open Respir Med J       Date:  2010-03-30

6.  Increased expression of the secretory leukocyte proteinase inhibitor in Wegener's granulomatosis.

Authors:  S Ohlsson; R Falk; J J Yang; K Ohlsson; M Segelmark; J Wieslander
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

7.  Neutrophil elastase modulates cytokine expression: contribution to host defense against Pseudomonas aeruginosa-induced pneumonia.

Authors:  Rym Benabid; Julien Wartelle; Laurette Malleret; Nicolas Guyot; Sophie Gangloff; François Lebargy; Azzaq Belaaouaj
Journal:  J Biol Chem       Date:  2012-08-27       Impact factor: 5.157

8.  Potential role of recombinant secretory leucoprotease inhibitor in the prevention of neutrophil mediated matrix degradation.

Authors:  C G Llewellyn-Jones; D A Lomas; R A Stockley
Journal:  Thorax       Date:  1994-06       Impact factor: 9.139

Review 9.  Attacking the multi-tiered proteolytic pathology of COPD: new insights from basic and translational studies.

Authors:  Uros V Djekic; Amit Gaggar; Nathaniel M Weathington
Journal:  Pharmacol Ther       Date:  2008-10-31       Impact factor: 12.310

10.  Structure basis 1/2SLPI and porcine pancreas trypsin interaction.

Authors:  Kei Fukushima; Takashi Kamimura; Midori Takimoto-Kamimura
Journal:  J Synchrotron Radiat       Date:  2013-09-29       Impact factor: 2.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.